Monday AM Earnings Wire
May 11, 2026
Eight Q1 prints this morning plus a delayed alert from last week. The verdict up front. Today was light on fresh clinical data and heavy on regulatory progress, commercial momentum, and balance sheet moves. Six beats, one miss, and several names that strengthened their position for the back half of 2026. The data-rich windows are still ahead. Working lowest priced name to highest.
Heron Therapeutics (HRTX). Friday close $1.21.
The one miss in the batch. Total Q1 net revenue $34.7 million, down 10.8 percent year over year from $38.9 million. The story is a portfolio rotation that has not yet caught up to itself.
The good. Acute Care up 32.3 percent year over year. ZYNRELEF up 27.3 percent to $10.2 million. APONVIE up 50.2 percent to $3.4 million. APONVIE’s permanent product-specific J-code went active April 1, 2026, which is the single biggest near-term access unlock for the rest of 2026. The Fifth Consensus Guidelines for PONV management named APONVIE as the only FDA-approved IV NK-1 antagonist in the category. ZYNRELEF continues to benefit from NOPAIN Act reimbursement across 110 million commercial covered lives.
The bad. Oncology Supportive Care down 26.3 percent, with CINVANTI down 20.2 percent to $20.5 million. SUSTOL in managed wind-down. The Acute Care growth is real but not yet large enough to offset the Oncology decline. Cash $44.8 million against reaffirmed full year guidance of $173 million to $183 million implies a meaningful Q2 through Q4 ramp. That requires the planned Q3 2026 sales force expansion and CINVANTI stabilization to deliver. CINVANTI Baxter patent litigation settled, dismissed April 28, 2026, removing one overhang. ZYNRELEF prefilled syringe stability data Q1 2027.
M&A Hunter read. Turnaround setup with cash overhang and revenue trajectory that has to inflect inside three quarters. Needs verification work before formal score lock.
Gain Therapeutics (GANX). Friday close $1.82.
Microcap that turned out to be more interesting than the headline EPS beat suggested.
The biomarker data matters. GT-02287 is an allosteric GCase modulator for Parkinson’s disease with or without GBA1 mutation. 14 of 16 Phase 1b extension participants completed Day 150 dosing as of March 2026. MDS-UPDRS scores stable over 150 days. In participants with elevated baseline glucosylsphingosine (GluSph) in cerebrospinal fluid, GluSph decreased by an average of 81 percent after 90 days of treatment. DOPA decarboxylase also decreased in the same elevated-baseline cohort.
81 percent CSF biomarker reduction is meaningful target engagement signal in a neurodegenerative indication.
The platform widened too. GT-04686, a new GCase allosteric modulator from the Magellan platform, is ready for IND-enabling studies in Parkinson’s. Activity in vitro and in vivo across both mutated and wildtype GBA1 fibroblasts. Motor and non-motor function restoration in animal models.
The wall. Cash $16.5 million against quarterly opex roughly $5.4 million. Roughly three quarters of runway absent a raise. Financing risk is the dominant near-term variable, not the data.
Catalyst stack. FDA IND clearance expected Q2 2026. Phase 2 start Q3 2026. Full Phase 1b clinical study results Q4 2026. Additional Phase 1b detail at the 3rd International GBA1 Meeting in Phoenix later this month.
M&A Hunter read. Real biomarker signal, real platform breadth, but the financing has to clear before any of it matters. Buyer profile is real (BIIB, AbbVie, Lilly, Novartis all active in PD), with MJFF and Silverstein Foundation backing as credibility signals. Score qualitatively Speculative-to-Watch pending Q2 financing visibility.
Lexeo Therapeutics (LXEO). Friday close $5.83.
Clinical-stage genetic medicine for cardiovascular disease. Today’s release sharpened the pivotal trial timing and added a meaningful manufacturing and re-dosing signal.
LX2006 (gene therapy for Friedreich ataxia) Phase 1/2 interim continues to show sustained or deepening improvements across cardiac and neurologic measures. Statistically significant mFARS improvement vs propensity-matched UNIFAI natural history control, n=17, p=0.003. No Grade 3 or higher SAEs to date.
The piece that changes the longer-term platform read. Nonhuman primate sequential dosing data showed that eight weeks after IV LX2006 administration, NHPs received LX2006 directly to the cerebellum or cerebrospinal fluid, and therapeutic levels of cerebellar vector genome copies were detected via both routes despite pre-existing immunity to the vector. AAV re-dosing optionality is one of the hardest problems in the gene therapy space. If this holds in humans, it converts LX2006 from one-shot to repeatable.
The SUNRISE-FA 2 pivotal trial protocol and statistical analysis plan were submitted to FDA in February 2026. FDA feedback expected Q2 2026. Pivotal trial initiation now narrowed to Q2 2026.
New programs disclosed. LX2022 (TNNI3 replacement for hypertrophic cardiomyopathy, ASGCT preclinical readout in May using a porcine model Lexeo developed specifically for TNNI3-targeted therapies). LX2020 (PKP2 arrhythmogenic cardiomyopathy, 10 patients dosed, no clinically significant complement activation, 12-month data Q4 2026).
Governance signal. Laura Sepp-Lorenzino, Ph.D., former Intellia CSO, joined the board. Prior senior roles at Alnylam and Vertex. That is high-quality validation for a sub-$500 million genetic medicine company.
Cost discipline. R&D down to $15.7 million from $17.2 million year over year. G&A down sharply to $6.6 million from $16.6 million. Net loss $20.2 million Q1.
Cash $227.6 million, runway into 2028.
M&A Hunter read. Defensible Dual Catalyst territory when formally scored. Buyer profile SRPT, BMRN, REGN. Pivotal initiation Q2 2026 is the next score-moving catalyst.
Intellia Therapeutics (NTLA). Friday close $14.09.
The first in vivo CRISPR gene editing platform aiming for commercial launch.
Lonvo-z (lonvoguran ziclumeran) for hereditary angioedema. Phase 3 HAELO topline reported in April. Primary endpoint hit. 87 percent reduction in monthly attack rate vs placebo (0.26 vs 2.10, p less than 0.0001) over the six-month efficacy window. All key secondary endpoints hit with statistical significance.
The headline number that matters. 62 percent of lonvo-z patients were entirely attack free AND therapy free during the six-month window vs 11 percent placebo (p less than 0.0001). Current HAE standard of care is chronic prophylaxis every two to four weeks for life. Lonvo-z is one infusion, attack free, off therapy. All crossover patients remained free from long-term prophylaxis as of the data cutoff.
Safety. No serious adverse events in the lonvo-z arm. All TEAEs Grade 1 or 2. Most common were infusion-related reactions, headache, and fatigue.
Rolling BLA submission to FDA initiated in April under the RMAT designation. Completion targeted H2 2026. Potential US launch first half of 2027. Additional HAELO data at EAACI Congress June 12 through 15 in Istanbul (abstract 100217).
ATTR program restarted in Q1. FDA lifted clinical holds on both MAGNITUDE (ATTR-CM) and MAGNITUDE-2 (ATTRv-PN) Phase 3 trials. Patient screening underway. MAGNITUDE-2 enrollment completion targeted H2 2026. Regeneron co-leads nex-z development.
Balance sheet. Cash $517.2 million as of March 31, plus $207 million April public offering, roughly $724 million pro forma. Runway well beyond H1 2027 launch excluding any lonvo-z commercial revenue. R&D down sharply to $80.7 million from $108.4 million year over year. G&A up to $34.8 million on commercial buildout. Net loss $96.2 million.
M&A Hunter read. Dual Catalyst territory when formally scored. The M&A side caps because Intellia is now building toward in-house BLA and commercial launch, which is the opposite of preparing for a sale. Acquirers wait for launch curve visibility. Buyer profile if it materializes: Vertex (CRISPR fluency), REGN (already a nex-z partner), AZN (cardiovascular plus gene therapy build).
Dyne Therapeutics (DYN). Friday close $17.61.
The cleanest late-stage neuromuscular setup in the batch.
Z-rostudirsen (DYNE-251) for DMD exon 51 skipping. Positive FDA pre-BLA meeting completed. BLA submission for US Accelerated Approval on track for Q2 2026. Potential US launch Q1 2027 assuming Priority Review.
The dystrophin data presented at MDA in March is striking. Four participants dosed at 20 mg/kg every four weeks for 12 plus months (range 67 to 104 weeks). Unadjusted dystrophin production reached an average of 9.48 percent of normal (n=4) vs 0.52 percent at baseline (n=3). Muscle content-adjusted dystrophin reached 18.33 percent of normal vs 1.47 percent baseline. For context, the approved exon-skipping antisense oligonucleotides for DMD have historically generated single-digit dystrophin percentages. Dyne is producing meaningfully higher exposure with a comparable safety profile.
Safety. 86 participants in DELIVER followed up to 36 months. Favorable safety profile. Most related TEAEs mild or moderate (pyrexia and headache most common). No related serious TEAEs in the registrational expansion cohort.
Phase 3 global confirmatory trial of z-rostudirsen aligned with FDA on design and protocol. Initiation Q2 2026.
DM1 program. Z-basivarsen (DYNE-101) ACHIEVE registrational expansion cohort hit the 60-patient enrollment target. Dyne is letting screening overflow, expecting completion above 60 participants in Q2 2026. Data Q1 2027 to support potential BLA early Q3 2027. Phase 3 HARMONIA already initiated in March 2026.
Platform depth. Four additional DMD candidates targeting exons 53, 45, 44, and 55. FORCE platform CNS preclinical data at ASGCT on Wednesday May 13 at 10:30 AM ET shows blood-brain barrier penetration in nonhuman primates. Platform expansion into CNS is meaningful for FSHD, Pompe, and any neuromuscular indication with a CNS component.
Cash $972.2 million, runway into Q1 2028. R&D $100.9 million Q1. G&A $24.4 million on commercial buildout. Net loss $120.9 million.
M&A Hunter read. Dual Catalyst territory when formally scored. The most advanced commercial-stage neuromuscular setup in the cohort, with BLA in three months, four follow-on assets, and platform expansion into CNS. Buyer profile SRPT (offensive or defensive), BMRN, Novartis, Roche.
Definium Therapeutics (DFTX). Delayed alert, original print May 7.
Already in the tracker from last week. The platform note here is the catalyst sequencing.
Three Phase 3 topline readouts for DT120 ODT inside five months.
Emerge (MDD, 149 patients) topline late Q2 2026.
Voyage (GAD, 214 patients) topline early Q3 2026.
Panorama (GAD, over 200 patients with dose-control arm) topline late Q3 2026.
Plus Ascend (MDD, 175 patients) first patient dosing Q2 2026. Plus Haven (PTSD, 200 patients, CAPS-5 Week 8 primary endpoint) Phase 3 expected to initiate in 2027.
DT120 ODT is Definium’s optimized LSD formulation using Catalent Zydis fast-dissolve technology. Tartrate salt of lysergide, partial agonist at 5-HT2A receptors.
Cash $373.4 million. Runway into 2028.
The binary cluster matters. Three Phase 3 readouts in five months in MDD and GAD is the most compressed psychedelics catalyst stack in the public market. MDD is the headline binary because placebo response in MDD is mechanically the hardest bar. GAD trials clear lower placebo response thresholds. The Haven PTSD addition positions Definium directly into the gap Lykos created in 2024 but with a different molecule and a controlled-dose ODT delivery model rather than high-dose assisted therapy.
M&A Hunter read. Speculative-to-High-Conviction Pending Late Q2 Print. Pre-print, the cleanest binary catalyst setup in psychedelics. Post-print, the score either locks high or resets.
Forte Biosciences (FBRX). Small cap autoimmune.
Not previously in the tracker. Sneaking into the batch because the setup is interesting.
FB102 is a proprietary anti-CD122 monoclonal antibody. CD122 is the IL-2 and IL-15 receptor beta subunit, expressed on memory T cells and NK cells. Blocking CD122 selectively suppresses pathogenic memory T-cell responses without broadly immunosuppressing. The mechanism is differentiated against the JAK-dominated competitor field in autoimmune.
Three indications in active clinical development.
Celiac disease. FB102 Phase 2 topline 2026. Fast Track Designation just granted by FDA. Phase 1b celiac data was positive in June 2025. Celiac is the platform-defining indication. Roughly 2 million diagnosed in the US, 3 million in EU. No approved disease-modifying therapeutics.
Vitiligo. Phase 1b ongoing. Topline expected shortly per the CEO comment. Near-term binary.
Alopecia areata. Phase 1b ongoing. Topline 2026.
Cash $58.2 million Q1 plus $172.5 million raised in April 2026. Pro forma roughly $230 million. Roughly 9 to 10 quarters of runway. Funds all three 2026 catalysts and well beyond. Share count post raise approximately 24.5 million shares. Small float.
M&A Hunter read. Defensible Dual Catalyst territory when formally scored. Buyer profile BMY, Lilly, AbbVie, Sanofi, JNJ, all active in immunology. The vitiligo Phase 1b topline expected shortly is the nearest binary. Celiac Phase 2 is the platform binary.
Liquidia Corporation (LQDA). Friday close $42.30.
The cleanest commercial story in the batch.
YUTREPIA (inhaled treprostinil for PAH and PH-ILD) Q1 net product sales $129.9 million. Total revenue $132.9 million including $3.0 million service. Third consecutive quarter of profitability. Net income $52.9 million. Adjusted EBITDA $71.2 million. Diluted EPS $0.52. Cash up $32.1 million sequentially to $222.8 million. Now paying income tax ($3.9 million Q1), which is a clean signal that the launch curve is real and management expects to keep paying.
Commercial launch metrics through April 30. 4,500 plus unique patient prescriptions since June 2025 launch. 3,750 plus patients started on treatment. Prescription-to-start conversion at or above 85 percent. 980 plus total prescribers. Approximately 270 prescribers have prescribed YUTREPIA to 5 or more patients (up 25 percent since end of February).
Pipeline. L606 (liposomal treprostinil suspension) is in the pivotal Phase 3 Re-Spire study for PH-ILD, actively screening. Phase 4 Tyvaso and Tyvaso DPI transition study also actively screening. L606 is the next platform expansion catalyst.
R&D up to $12.6 million from $7.0 million year over year on L606 ramp. SG&A up to $46.9 million from $30.1 million on commercial buildout. Legal fees down $3.7 million as Liquidia’s UTHR litigation winds down post-Liquidia win.
M&A Hunter read. Off-patent Tyvaso challenger that won the patent fight. Commercial-stage cardiopulmonary. Three consecutive profitable quarters. Buyer profile JNJ, JAZZ, possibly UTHR defensively. Score qualitatively Growth Play. The launch curve has not normalized yet.
Apogee Therapeutics (APGE). Friday close $83.03. Locked Dual Catalyst, M&A 82, Growth 84.
The thesis lock from the May 4 review holds. Today’s release is confirming data, not thesis-changing data.
Zumilokibart Phase 2 APEX Part A 52-week data continues to look strong. Of EASI-75 responders at Week 16, 75 percent (every 3-month dosing) and 85 percent (every 6-month dosing) maintained response at Week 52. Of IGA 0/1 responders at Week 16, 86 percent (Q3M) and 78 percent (Q6M) maintained response. Across the full treated population, responses improved through Week 52. EASI-90 at 75 percent (Q3M) and 48 percent (Q6M) at Week 52. EASI-100 at 41 percent (Q3M) and 19 percent (Q6M).
AAD late-breaking session added EASI-90 maintenance data and lesional skin transcriptome improvements across Type 1, Type 2, and Type 3 inflammatory pathways. That is a broader mechanism signal than IL-13 monotherapy framing alone.
Catalyst stack. APEX Phase 2 Part B 16-week induction dose data Q2 2026 (the next score-moving event). Phase 3 in AD initiation 2H 2026.
Pipeline breadth. APG279 (zumilokibart plus APG990) Phase 1b head-to-head vs DUPIXENT in AD fully enrolled at 86 patients. Interim 24-week data H2 2026. APG273 (zumilokibart plus APG333) respiratory program details later in 2026. Asthma Phase 1b positive interim disclosed January 2026. EoE trials to be detailed.
Balance sheet. $403 million upsized public equity offering closed in March. Cash $1.3 billion as of March 31 (vs $902.9 million Dec 31). Runway into 2029 through planned BLA filing in AD. R&D $60.8 million Q1. G&A $22.0 million. Net loss $74.1 million.
M&A Hunter read. Dual Catalyst lock at 82 by 84 holds. Buyer profile Lilly (defense), SNY, AZN. Cap at 82 because $5 billion market cap is meaningful and Phase 3 is not yet enrolling at scale. The Part B Q2 readout is the next event that could either confirm the lock or move it.
The big picture
Today was housekeeping. Six beats and one miss, but the actual story across the cohort is the calendar.
The data-rich windows are all ahead.
DRTS REGAIN interim hit today (separate post). DRTS ASCO oral pancreatic data May 29 through June 2.
APGE APEX Part B 16-week induction Q2 2026.
DYN BLA submission Q2 2026.
NTLA EAACI HAELO additional data June 12 through 15.
LXEO multiple presentations at ASGCT this week.
DFTX Emerge MDD topline late Q2.
GANX Phoenix GBA1 Meeting later this month.
FBRX vitiligo Phase 1b shortly.
This week is ASGCT week. The annual gene and cell therapy meeting runs in Boston starting Tuesday. Multiple names in this cohort present, including LXEO with multiple presentations on LX2006 plus the LX2022 preclinical TNNI3 HCM data, and DYN with the FORCE platform CNS data on Wednesday at 10:30 AM ET.
The setups are doing the work. Stay disciplined.